Pilot Trial of pTVG-HP DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer

Trial Profile

Pilot Trial of pTVG-HP DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 02 Aug 2017

At a glance

  • Drugs MVI 816 (Primary) ; Pembrolizumab (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 02 Aug 2017 According to Madison Vaccines media release, first patient has been dosed in an expanded cohort of 20 patients with metastatic, castrate-resistant prostate cancer, who will be offered the combination regimen for up to 48 weeks
    • 27 Jun 2017 Planned End Date changed from 1 Sep 2019 to 1 Apr 2019.
    • 27 Jun 2017 Planned primary completion date changed from 1 Sep 2018 to 1 Apr 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top